All lobbying filings

Forward Global

Forward Global filed a Q3 report for Quoin Pharmaceuticals, Inc. on October 20, 2026, reporting $20,000 in lobbying income.

Lobbying for Quoin Pharmaceuticals, Inc. · Development and commercialization of therapeutic drug products that treat rare diseases.

As filed: FORWARD GLOBAL for QUOIN PHARMACEUTICALS, INC.

All filings by Forward Global · Everything Quoin Pharmaceuticals, Inc. has reported

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2026

July 1 - Sep 30 · Posted Oct 20, 2026

Income

$20,000

What the client paid this registrant for the period.

Client based in

Virginia

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 1

Health Issues

Advocating for robust support of the rare disease community at large, including continued government funding for rare disease research and development, clinical trial reform to accelerate the path to new treatments, and financial incentives such as the Rare Pediatric Disease Designation and Priority Review Voucher Programs that encourage investment in this space.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.